Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azenosertib Monotherapy in Advanced Solid Tumors
NCT04158336Phase 1Completed
- Sponsor
- Zentalis Pharmaceuticals
- Start
- Nov 2019
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of azenosertib in solid tumor, uterine serous carcinoma (USC) and High-Grade Serous Ovarian Carcinoma (HGSOC) (3 arms), sponsored by Zentalis Pharmaceuticals. Primary endpoints: Maximum Tolerated Dose at 1 year, Pharmacokinetics at 6 months and 1 more. Started Nov 2019; status: completed.
02
Drugs
azenosertib
03
Conditions
solid tumoruterine serous carcinoma (USC)High-Grade Serous Ovarian Carcinoma (HGSOC)
Beyond the preview
Go deeper on NCT04158336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04158336.